Since MAP2K1 mutations were only identified in MAPK wildtype cases, we further analyzed 286 MAPK wildtype PTC and 289 MAPK wildtype CRC cases as validation cohort. This evidence concerns the gene MAP2K1 and colorectal carcinoma.